Clinical Trial

Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer

Study acronym: BACON
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07489300
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Enrollment 40 participants
Start Date 2026-03-30
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24